EPS for PharMerica Corporation (PMC) Expected At $0.47

July 31, 2017 - By Marie Mckinney

 EPS for PharMerica Corporation (PMC) Expected At $0.47
Investors sentiment decreased to 0.96 in 2016 Q4. Its down 0.01, from 0.97 in 2016Q3. It turned negative, as 19 investors sold PharMerica Corporation shares while 51 reduced holdings. 17 funds opened positions while 50 raised stakes. 27.89 million shares or 2.74% less from 28.68 million shares in 2016Q3 were reported.
Pub Sector Pension Invest Board has 0.01% invested in PharMerica Corporation (NYSE:PMC). Manufacturers Life Insurance The holds 0% of its portfolio in PharMerica Corporation (NYSE:PMC) for 20,427 shares. International Group Inc Inc reported 21,844 shares. Citigroup reported 62,380 shares or 0% of all its holdings. Swiss Savings Bank has 49,800 shares for 0% of their portfolio. California-based Reilly Limited Com has invested 0% in PharMerica Corporation (NYSE:PMC). Comerica Bankshares has invested 0.01% of its portfolio in PharMerica Corporation (NYSE:PMC). Goldman Sachs reported 0% in PharMerica Corporation (NYSE:PMC). Blackrock Inv Lc invested 0% of its portfolio in PharMerica Corporation (NYSE:PMC). Smith Graham & Advsrs Lp, Texas-based fund reported 433,009 shares. Barclays Public Limited Co reported 0% in PharMerica Corporation (NYSE:PMC). Lsv Asset Management accumulated 421,550 shares. Jpmorgan Chase & reported 254,156 shares stake. Paloma Prtnrs Management Company reported 0% stake. Balyasny Asset Management Ltd Liability Com has invested 0.01% in PharMerica Corporation (NYSE:PMC).

Analysts expect PharMerica Corporation (NYSE:PMC) to report $0.47 EPS on August, 8.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.47 EPS. PMC’s profit would be $14.61M giving it 13.38 P/E if the $0.47 EPS is correct. After having $0.42 EPS previously, PharMerica Corporation’s analysts see 11.90 % EPS growth. The stock decreased 2.14% or $0.55 during the last trading session, reaching $25.15. About 109,843 shares traded. PharMerica Corporation (NYSE:PMC) has declined 3.31% since August 1, 2016 and is downtrending. It has underperformed by 20.01% the S&P500.

PharMerica Corporation (NYSE:PMC) Ratings Coverage

Among 3 analysts covering Pharmerica (NYSE:PMC), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Pharmerica had 6 analyst reports since August 10, 2015 according to SRatingsIntel. Barrington Research maintained PharMerica Corporation (NYSE:PMC) rating on Monday, August 10. Barrington Research has “Outperform” rating and $38.0 target. On Monday, March 14 the stock rating was downgraded by UBS to “Neutral”. Bank of America maintained PharMerica Corporation (NYSE:PMC) on Tuesday, June 7 with “Buy” rating. Zacks downgraded the stock to “Hold” rating in Monday, August 17 report. Barrington Research maintained it with “Outperform” rating and $34 target in Tuesday, May 10 report. The company was upgraded on Monday, August 10 by UBS.

PharMerica Corporation is an institutional pharmacy services company. The company has market cap of $782.03 million. The Firm services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. It has a 37.42 P/E ratio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: